Table 1

Baseline characteristics of LN patients included in the study (n = 46)

Active LN

Without active LN


History of LN

No history of LN


Total number

22

10

14

Women/men

19/3

7/3

13/1

Age (years, mean ± SD)

35 ± 10*

46 ± 14

37 ± 10

SLEDAI (mean ± SD)

13 ± 3 **, ##

3 ± 2

3 ± 3

Anti-dsDNA, E/ml (median, range)

230 (3 to 1,000)*, ##

5 (3 to 432)

81 (3 to 1,000)

C3 g/l (median, range)

0.54 (0.05 to 1.03)**, ##

1.13 (0.54 to 1.48)

0.99 (0.31 to 1.43)

C4 g/l (median, range)

0.08 (0.03 to 0.48)*

0.23 (0.04 to 0.30)$

0.12 (0.05 to 0.24)

Previous biopsy proven LN (yes/no)

9/13

10/0

0/14

Serum creatinine µmol/l

94 ± 78#

80 ± 26

62 ± 13

Urinary analysis

Proteinuria g/24 h (mean ± SD)

2.8 ± 3.2**, ##

0.3 ± 0.3$,$

0.0 ± 0.1

Dysmorphic erythrocytes in %

36 %

0.%

0.%

CD4+T-cells/ml (median, range)

128 (0 to 1,250)**, ##

9 (0 to 63)

0 (0 to 136)

CD8+T-cells/ml (median, range)

177 (0 to 1,388)**, ##

13 (0 to 118)

17 (0 to 92)


The patients were sub-grouped into biopsy proven LN (n = 22) and patients without active LN (n = 24). The patients without active LN were further sub-grouped into patients with biopsy proven LN in the past (n = 10) and patients without renal involvement (n = 14). Significant differences between patients with active LN and patients with biopsy proven LN in the past without current activity are indicated (P <0.05 = *, P <0.005 = **). Significant differences between active LN and patients without renal involvement are indicated (P <0.05 =#, P <0.005 =##). Significant differences between patients with biopsy proven LN in the past without current activity and patients without renal involvement are indicated (P <0.05 =$, P <0.005 =$$).

Dolff et al. Arthritis Research & Therapy 2013 15:R36   doi:10.1186/ar4189

Open Data